Apollon Wealth Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$134K Sell
14,152
-715
-5% -$5.72K ﹤0.01% 1561
2026
Q2
$130K Buy
+14,867
New +$113K ﹤0.01% 1519
2023
Q2
– Sell
-13,600
Closed -$24.8K – 965
2023
Q1
$24.8K Buy
+13,600
New +$42.3K ﹤0.01% 856

Other funds holding IBRX

Apollon Wealth Management's IBRX Position: Q3 2026 in Review

Apollon Wealth Management reduced its ImmunityBio (IBRX) stake by 4.8% in Q3 2026, selling an estimated $5.72K and leaving 14,152 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Apollon Wealth Management first reported a position in IBRX in Q1 2023 and has held it in 3 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Apollon Wealth Management held 14,152 shares of ImmunityBio worth $134K as of Q3 2026.
  • Apollon Wealth Management sold 715 ImmunityBio shares in Q3 2026, an estimated $5.72K.
  • ImmunityBio made up ﹤0.01% of Apollon Wealth Management's portfolio in Q3 2026, its #1561 holding.
  • Apollon Wealth Management first reported a position in ImmunityBio in Q1 2023 and has held it in 3 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.